Endocrine System Diseases  >>  smart insulin (MK-2640)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
smart insulin (MK-2640) / Merck (MSD)
NCT02269735: A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)

Completed
1
74
NA
MK-2640, Regular Human Insulin (RHI), Dextrose, Insulin aspart, Rescue medication
Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitus
07/16
07/16

Download Options